Investigational drug · Phase 3
SCTB14
Not approved by FDA. In 2 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Non-Small Cell Lung Carcinoma (NSCLC), Advanced Malignant Solid Tumours.
Phase 3Last checked: Nov 19, 2026Latest source record: Jan 23, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
2
2 still active
All registered trials
2
Any phase or sponsor naming "SCTB14"
First trial start
2024
Apr 30, 2024
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "SCTB14", any sponsor or status.
Conditions studied
As listed on its trial records.
- Non-Small Cell Lung Carcinoma (NSCLC)
- Advanced Malignant Solid Tumours
Approved drugs for the same conditions: Non-small cell lung cancer · Oncology
Largest trials
Live from ClinicalTrials.gov: studies naming "SCTB14" as an intervention, largest first.
- Aims to Explore the Safety, Tolerability, and Preliminary Efficacy of SCTB14 in Adult Patients With Advanced Malignant Solid Tumours.Not yet recruiting
Sinocelltech Ltd.Industry
NCT06304818 · 515 participants (planned) · Start Apr 30, 2024 · Primary completion Dec 30, 2027
Drug: SCTB14 · For: Advanced Malignant Solid Tumours
- A Study to Evaluate the Safety and Tolerability of SCTB14 as First-Line Therapy in Non-Small Cell Lung Cancer.Pivotal-lookingRecruiting
Sinocelltech Ltd.Industry
NCT07362459 · 246 participants (planned) · Start Dec 30, 2025 · Primary completion Jul 2027
Drug: SCTB14; Pembrolizumab · For: Non-Small Cell Lung Carcinoma (NSCLC)
Sites: Shanghai, China
Newest research
PubMed records naming it or its code names, newest first.
No PubMed records name it yet, which is common for early code-named drugs.
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.